Cargando…
Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study
BACKGROUND: The assessment of the sentinel lymph node is a cornerstone of melanoma staging. However, ~80% of sentinel lymph node biopsies (SLNB) are negative and nontherapeutic, and patients are unnecessarily exposed to surgery‐related complications. Here, we gauged the potential of the Merlin assay...
Autores principales: | Hieken, Tina J., Sadurní, Mariana B., Quattrocchi, Enrica, Kobic, Ajdin, Sominidi‐Damodaran, Sindhuja, Dwarkasing, Jvalini T., Meerstein‐Kessel, Lisette, Bridges, Alina G., Meves, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203934/ https://www.ncbi.nlm.nih.gov/pubmed/35100440 http://dx.doi.org/10.1111/ijd.16056 |
Ejemplares similares
-
Cost evaluation of the Merlin assay for predicting melanoma sentinel lymph node biopsy metastasis
por: Thao, Viengneesee, et al.
Publicado: (2022) -
Clinicopathologic models predicting non‐sentinel lymph node metastasis in cutaneous melanoma patients: Are they useful for patients with a single positive sentinel node?
por: Rentroia‐Pacheco, Barbara, et al.
Publicado: (2021) -
Validation of CP‐GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study
por: Yousaf, Ahmed, et al.
Publicado: (2021) -
Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
por: Bellomo, Domenico, et al.
Publicado: (2020) -
Breslow thickness 2.0: Why gene expression profiling is a step toward better patient selection for sentinel lymph node biopsies
por: Sadurní, Mariana B., et al.
Publicado: (2022)